DALLAS, Dec. 9, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today confirmed plans to publish an update tomorrow on Tuesday, December 10, 2019 to present capital infusion plans for the company's cannabis extract biopharmaceutical business valued at $50 million. ALYI is proceeding with a capital infusion plan to accelerate the growth of its cannabis biopharmaceutical technology. KALY has recently announced receiving two inquiries into the acquisition of the company's cannabis biopharmaceutical technology valuing the technology at $50 million. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions (see below). Doctors working with KALY on the treatment developments have compared KALY's technology to GW Pharmaceuticals' and indicated the KALY solutions could be superior to GW Pharma's. KALY management has recently announced that in response to the two acquisition opportunities, that the company is introducing a third option that would not involve a sale of KALY's biopharmaceutical technology asset but would otherwise restructure the asset within KALY's current corporate structure to facilitate a major infusion of investment capital.
KALY's cannabis biopharmaceutical technology intellectual property portfolio contains a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025.
In addition to KALY's ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY's U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration.
To stay abreast of the latest developments and learn more about the company visit https://www.kali-extracts.com/.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
SOURCE Kali-Extracts, Inc.
These press releases may also interest you